1
|
Burgué H, Trensz P, Mathelin C, Schohn A. [Can health forums dedicated to breast cancer be useful to caregivers? Analysis of initial messages on the National League Against Cancer forum over a one-year period]. Gynecol Obstet Fertil Senol 2024:S2468-7189(24)00042-4. [PMID: 38342238 DOI: 10.1016/j.gofs.2024.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 02/04/2024] [Accepted: 02/06/2024] [Indexed: 02/13/2024]
Abstract
OBJECTIVES Forums are a source of health information and exchange. They can be studied to determine patients' needs and improve caregivers' practices. The aim of this study was to identify the needs of breast cancer patients based on messages posted on a discussion forum. METHODS Initial messages posted in 2021 on the Ligue nationale contre le cancer (LNCC) breast cancer forum were analyzed quantitatively. Message content was classified into three categories: testimonial, request for advice or request for medical opinion. The tone of the message (positive, neutral, or negative) was recorded. The temporality of the illness during which the patient expressed herself was defined. Analysis was carried out on the initial messages using the Chi2, Fisher, and Kruskal-Wallis tests, with a significance level of<0.05. RESULTS In 2021, 640 initial messages posted on the LNCC forum dedicated to breast cancer were analyzed. Messages were posted by 312 authors, including 275 patients and 37 family members. Three main types of messages were identified: requests for medical advice (n=339), advice (n=164), and testimonials (n=137). Requests for medical advice elicited fewer responses than testimonials (P<0.001). A need for supportive care was identified in 42.8% of messages, mostly concerning social (17.3%) and psychological (13%) care. CONCLUSION Our study revealed a need for more information especially regarding the social impact of the disease and the side-effects of treatment. The period of greatest need of information was the diagnostic waiting time. However, patients using discussion forums are not representative of all women with breast cancer and our results should not be generalized to all patients treated for breast cancer.
Collapse
Affiliation(s)
- Hélène Burgué
- Département de médecine générale, médecine générale de Dijon, université de Strasbourg, Strasbourg, France
| | - Philippe Trensz
- Pôle évaluation, soins support et accompagnement, ICANS, avenue Albert-Calmette, 67200 Strasbourg, France
| | - Carole Mathelin
- Service de chirurgie, ICANS, CHRU, avenue Albert-Calmette, 67200 Strasbourg, France.
| | - Anna Schohn
- Pôle évaluation, soins support et accompagnement, ICANS, avenue Albert-Calmette, 67200 Strasbourg, France
| |
Collapse
|
2
|
Mallard J, Hucteau E, Bender L, Moinard‐Butot F, Rochelle E, Boutonnet L, Grandperrin A, Schott R, Pflumio C, Trensz P, Kalish‐Weindling M, Charles A, Gény B, Favret F, Pivot X, Hureau TJ, Pagano AF. A single chemotherapy administration induces muscle atrophy, mitochondrial alterations and apoptosis in breast cancer patients. J Cachexia Sarcopenia Muscle 2024; 15:292-305. [PMID: 38183352 PMCID: PMC10834353 DOI: 10.1002/jcsm.13414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Revised: 11/13/2023] [Accepted: 11/20/2023] [Indexed: 01/08/2024] Open
Abstract
BACKGROUND Breast cancer patients are commonly treated with sequential administrations of epirubicin-cyclophosphamide (EC) and paclitaxel (TAX). The chronic effect of this treatment induces skeletal muscle alterations, but the specific effect of each chemotherapy agent is unknown. This study aimed to investigate the effect of EC or TAX administration on skeletal muscle homeostasis in breast cancer patients. METHODS Twenty early breast cancer patients undergoing EC followed by TAX chemotherapies were included. Two groups of 10 women were established and performed vastus lateralis skeletal muscle biopsies either before the first administration (pre) of EC (50 ± 14 years) or TAX (50 ± 16 years) and 4 days later (post). Mitochondrial respiratory capacity recording, reactive oxygen species production, western blotting and histological analyses were performed. RESULTS Decrease in muscle fibres cross-sectional area was only observed post-EC (-25%; P < 0.001), associated with a reduction in mitochondrial respiratory capacity for the complex I (CI)-linked substrate state (-32%; P = 0.001), oxidative phosphorylation (OXPHOS) by CI (-35%; P = 0.002), CI&CII (-26%; P = 0.022) and CII (-24%; P = 0.027). If H2 O2 production was unchanged post-EC, an increase was observed post-TAX for OXPHOS by CII (+25%; P = 0.022). We found a decrease in makers of mitochondrial content, as shown post-EC by a decrease in the protein levels of citrate synthase (-53%; P < 0.001) and VDAC (-39%; P < 0.001). Despite no changes in markers of mitochondrial fission, a decrease in the expression of a marker of mitochondrial inner-membrane fusion was found post-EC (OPA1; -60%; P < 0.001). We explored markers of mitophagy and found reductions post-EC in the protein levels of PINK1 (-63%; P < 0.001) and Parkin (-56%; P = 0.005), without changes post-TAX. An increasing trend in Bax protein level was found post-EC (+96%; P = 0.068) and post-TAX (+77%; P = 0.073), while the Bcl-2 level was decreased only post-EC (-52%; P = 0.007). If an increasing trend in TUNEL-positive signal was observed post-EC (+68%; P = 0.082), upregulation was highlighted post-TAX (+86%; P < 0.001), suggesting activation of the apoptosis process. CONCLUSIONS We demonstrated that a single administration of EC induced, in only 4 days, skeletal muscle atrophy and mitochondrial alterations in breast cancer patients. These alterations were characterized by reductions in mitochondrial function and content as well as impairment of mitochondrial dynamics and an increase in apoptosis. TAX administration did not worsen these alterations as this group had already received EC during the preceding weeks. However, it resulted in an increased apoptosis, likely in response to the increased H2 O2 production.
Collapse
Affiliation(s)
- Joris Mallard
- Biomedicine Research Center of Strasbourg (CRBS), UR 3072, “Mitochondrie, Stress oxydant et Plasticité musculaire”University of StrasbourgStrasbourgFrance
- Faculty of Sport SciencesUniversity of StrasbourgStrasbourgFrance
- Institut de Cancérologie Strasbourg Europe (ICANS)StrasbourgFrance
| | - Elyse Hucteau
- Biomedicine Research Center of Strasbourg (CRBS), UR 3072, “Mitochondrie, Stress oxydant et Plasticité musculaire”University of StrasbourgStrasbourgFrance
- Faculty of Sport SciencesUniversity of StrasbourgStrasbourgFrance
- Institut de Cancérologie Strasbourg Europe (ICANS)StrasbourgFrance
| | - Laura Bender
- Institut de Cancérologie Strasbourg Europe (ICANS)StrasbourgFrance
| | | | - Emma Rochelle
- Biomedicine Research Center of Strasbourg (CRBS), UR 3072, “Mitochondrie, Stress oxydant et Plasticité musculaire”University of StrasbourgStrasbourgFrance
- Faculty of Sport SciencesUniversity of StrasbourgStrasbourgFrance
| | - Lauréline Boutonnet
- Biomedicine Research Center of Strasbourg (CRBS), UR 3072, “Mitochondrie, Stress oxydant et Plasticité musculaire”University of StrasbourgStrasbourgFrance
| | - Antoine Grandperrin
- Biomedicine Research Center of Strasbourg (CRBS), UR 3072, “Mitochondrie, Stress oxydant et Plasticité musculaire”University of StrasbourgStrasbourgFrance
- Faculty of Sport SciencesUniversity of StrasbourgStrasbourgFrance
| | - Roland Schott
- Institut de Cancérologie Strasbourg Europe (ICANS)StrasbourgFrance
| | - Carole Pflumio
- Institut de Cancérologie Strasbourg Europe (ICANS)StrasbourgFrance
| | - Philippe Trensz
- Institut de Cancérologie Strasbourg Europe (ICANS)StrasbourgFrance
| | | | - Anne‐Laure Charles
- Biomedicine Research Center of Strasbourg (CRBS), UR 3072, “Mitochondrie, Stress oxydant et Plasticité musculaire”University of StrasbourgStrasbourgFrance
- Faculty of medicineUniversity of StrasbourgStrasbourgFrance
| | - Bernard Gény
- Biomedicine Research Center of Strasbourg (CRBS), UR 3072, “Mitochondrie, Stress oxydant et Plasticité musculaire”University of StrasbourgStrasbourgFrance
- Faculty of medicineUniversity of StrasbourgStrasbourgFrance
- Department of Physiology and Functional ExplorationsUniversity Hospital of StrasbourgStrasbourgFrance
| | - Fabrice Favret
- Biomedicine Research Center of Strasbourg (CRBS), UR 3072, “Mitochondrie, Stress oxydant et Plasticité musculaire”University of StrasbourgStrasbourgFrance
- Faculty of Sport SciencesUniversity of StrasbourgStrasbourgFrance
| | - Xavier Pivot
- Institut de Cancérologie Strasbourg Europe (ICANS)StrasbourgFrance
| | - Thomas J. Hureau
- Biomedicine Research Center of Strasbourg (CRBS), UR 3072, “Mitochondrie, Stress oxydant et Plasticité musculaire”University of StrasbourgStrasbourgFrance
- Faculty of Sport SciencesUniversity of StrasbourgStrasbourgFrance
| | - Allan F. Pagano
- Biomedicine Research Center of Strasbourg (CRBS), UR 3072, “Mitochondrie, Stress oxydant et Plasticité musculaire”University of StrasbourgStrasbourgFrance
- Faculty of Sport SciencesUniversity of StrasbourgStrasbourgFrance
| |
Collapse
|
3
|
Bender L, Pflumio C, Trensz P, Pierard L, Kalish M, Fischbach C, Petit T. Capecitabine efficacy after cycline-dependent-kinase 4/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer. Cancer Treat Res Commun 2023; 36:100738. [PMID: 37390791 DOI: 10.1016/j.ctarc.2023.100738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 06/20/2023] [Accepted: 06/22/2023] [Indexed: 07/02/2023]
Abstract
BACKGROUND The combination of endocrine treatment with cycline-dependent-kinase 4/6 inhibitor is the new standard of treatment in hormone receptor-positive HER2 negative metastatic breast cancer. The optimal subsequent treatment after CDK4/6 inhibitor remain unclear. As recommended by standard guidelines, capecitabine, an oral chemotherapy is a therapeutic option in endocrine resistant metastatic breast cancer. The objective of this study was to evaluate capecitabine efficacy after disease progression under combination of ET and CDK4/6 inhibitor in a hormone receptor positive metastatic breast cancer population. PATIENTS AND METHODS Patients progressing under CDK 4/6 inhibitor plus ET and treated with capecitabine, between January 2016 and December 2020, were retrospectively included. Primary endpoint was time to treatment failure (TTF) on capecitabine. Logistic regression were used to identify predictive factors: exclusive bone versus visceral metastases, first-line versus ≥ 2 lines of combination therapy, aromatase inhibitor (AI) versus fulvestrant. RESULTS Fifty-six patients with a 62-year median age (IC95% 42-81) were analyzed. The CDK 4/6 inhibitor and ET combination was prescribed in first-line setting in 26 patients (46%). Twenty-five patients (44%) had exclusive bone metastasis. Median TTF was 6.1 months. Six patients discontinued capecitabine due to toxicity. Outcomes were not significantly different regardless of metastases localization, ET, and treatment line of the combination of CDK 4/6 inhibitor and ET. Median PFS was 7.1 months. Median OS was 41.3 months. CONCLUSION Compared to other data of capecitabine prescribed in patients with hormonal resistant MBC, this retrospective study suggests that capecitabine remains effective after CDK 4/6 inhibitor plus ET progression, regardless of therapeutic-line setting and metastases localization. MICRO ABSTRACT Cycline dependant kinase 4/6 inhibitor plus endocrine therapy have become the standard of care in metastatic hormone receptor positive (HR+) breast cancer (BC). Few data reported the optimal subsequent therapy after progression under the combination. Capecitabine is a therapeutic option in endocrine resistant HR+/HER2- metastatic breast cancer. Data evaluating efficacy of capecitabine after disease progression on endocrine therapy plus cycline-dependant kinase 4/6 inhibitor are poor. This study showed a 6.1-month median time to treatment failure on capecitabine. Capecitabine remained effective regardless of therapeutic-line setting and metastases localization.
Collapse
Affiliation(s)
- L Bender
- Oncology Department, Institut de Cancérologie Strasbourg-Europe, 17 avenue Albert Calmette 672000 Strasbourg, France.
| | - C Pflumio
- Oncology Department, Institut de Cancérologie Strasbourg-Europe, 17 avenue Albert Calmette 672000 Strasbourg, France
| | - P Trensz
- Oncology Department, Institut de Cancérologie Strasbourg-Europe, 17 avenue Albert Calmette 672000 Strasbourg, France
| | - L Pierard
- Oncology Department, Institut de Cancérologie Strasbourg-Europe, 17 avenue Albert Calmette 672000 Strasbourg, France
| | - M Kalish
- Oncology Department, Institut de Cancérologie Strasbourg-Europe, 17 avenue Albert Calmette 672000 Strasbourg, France
| | - C Fischbach
- Oncology Department, Institut de Cancérologie Strasbourg-Europe, 17 avenue Albert Calmette 672000 Strasbourg, France
| | - T Petit
- Oncology Department, Institut de Cancérologie Strasbourg-Europe, 17 avenue Albert Calmette 672000 Strasbourg, France
| |
Collapse
|
4
|
Hucteau E, Mallard J, Pivot X, Schott R, Pflumio C, Trensz P, Favret F, Pagano AF, Hureau TJ. Exacerbated central fatigue and reduced exercise capacity in early-stage breast cancer patients treated with chemotherapy. Eur J Appl Physiol 2023:10.1007/s00421-023-05177-5. [PMID: 36939876 DOI: 10.1007/s00421-023-05177-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2022] [Accepted: 03/07/2023] [Indexed: 03/21/2023]
Abstract
PURPOSE The present study aimed to characterize the etiology of exercise-induced neuromuscular fatigue and its consequences on the force-duration relationship to provide mechanistic insights into the reduced exercise capacity characterizing early-stage breast cancer patients. METHODS Fifteen early-stage breast cancer patients and fifteen healthy women performed 60 maximal voluntary isometric quadriceps contractions (MVCs, 3 s of contraction, 2 s of relaxation). The critical force was determined as the mean force of the last six contractions, while W' was calculated as the force impulse generated above the critical force. Quadriceps muscle activation during exercise was estimated from vastus lateralis, vastus medialis and rectus femoris EMG. Central and peripheral fatigue were quantified via changes in pre- to postexercise quadriceps voluntary activation (ΔVA) and quadriceps twitch force (ΔQTw) evoked by supramaximal electrical stimulation, respectively. RESULTS Early-stage breast cancer patients demonstrated lower MVC than controls preexercise (- 15%, P = 0.022), and this reduction persisted throughout the 60-MVC exercise (- 21%, P = 0.002). The absolute critical force was lower in patients than in controls (144 ± 29N vs. 201 ± 47N, respectively, P < 0.001), while W' was similar (P = 0.546), resulting in lower total work done (- 23%, P = 0.001). This was associated with lower muscle activation in the vastus lateralis (P < 0.001), vastus medialis (P = 0.003) and rectus femoris (P = 0.003) in patients. Immediately following exercise, ΔVA showed a greater reduction in patients compared to controls (- 21.6 ± 13.3% vs. - 12.6 ± 7.7%, P = 0.040), while ΔQTw was similar (- 60.2 ± 13.2% vs. - 52.8 ± 19.4%, P = 0.196). CONCLUSION These findings support central fatigue as a primary cause of the reduction in exercise capacity characterizing early-stage breast cancer patients treated with chemotherapy. CLINICAL TRIALS REGISTRATION No. NCT04639609-November 20, 2020.
Collapse
Affiliation(s)
- Elyse Hucteau
- Biomedicine Research Centre of Strasbourg (CRBS), Mitochondria, Oxidative Stress, and Muscular Protection Laboratory (UR 3072), Strasbourg, France
- Faculty of Sport Sciences, European Centre for Education, Research and Innovation in Exercise Physiology (CEERIPE), University of Strasbourg, 4 rue Blaise Pascal, CS 90032, 67081, Strasbourg Cedex, France
- Institute of Cancerology Strasbourg Europe (ICANS), Strasbourg, France
| | - Joris Mallard
- Biomedicine Research Centre of Strasbourg (CRBS), Mitochondria, Oxidative Stress, and Muscular Protection Laboratory (UR 3072), Strasbourg, France
- Faculty of Sport Sciences, European Centre for Education, Research and Innovation in Exercise Physiology (CEERIPE), University of Strasbourg, 4 rue Blaise Pascal, CS 90032, 67081, Strasbourg Cedex, France
- Institute of Cancerology Strasbourg Europe (ICANS), Strasbourg, France
| | - Xavier Pivot
- Institute of Cancerology Strasbourg Europe (ICANS), Strasbourg, France
| | - Roland Schott
- Institute of Cancerology Strasbourg Europe (ICANS), Strasbourg, France
| | - Carole Pflumio
- Institute of Cancerology Strasbourg Europe (ICANS), Strasbourg, France
| | - Philippe Trensz
- Institute of Cancerology Strasbourg Europe (ICANS), Strasbourg, France
| | - Fabrice Favret
- Biomedicine Research Centre of Strasbourg (CRBS), Mitochondria, Oxidative Stress, and Muscular Protection Laboratory (UR 3072), Strasbourg, France
- Faculty of Sport Sciences, European Centre for Education, Research and Innovation in Exercise Physiology (CEERIPE), University of Strasbourg, 4 rue Blaise Pascal, CS 90032, 67081, Strasbourg Cedex, France
| | - Allan F Pagano
- Biomedicine Research Centre of Strasbourg (CRBS), Mitochondria, Oxidative Stress, and Muscular Protection Laboratory (UR 3072), Strasbourg, France
- Faculty of Sport Sciences, European Centre for Education, Research and Innovation in Exercise Physiology (CEERIPE), University of Strasbourg, 4 rue Blaise Pascal, CS 90032, 67081, Strasbourg Cedex, France
| | - Thomas J Hureau
- Biomedicine Research Centre of Strasbourg (CRBS), Mitochondria, Oxidative Stress, and Muscular Protection Laboratory (UR 3072), Strasbourg, France.
- Faculty of Sport Sciences, European Centre for Education, Research and Innovation in Exercise Physiology (CEERIPE), University of Strasbourg, 4 rue Blaise Pascal, CS 90032, 67081, Strasbourg Cedex, France.
| |
Collapse
|
5
|
Bischoff H, Bigot C, Moinard-Butot F, Pflumio C, Fischbach C, Kalish M, Kurtz JE, Pierard L, Demarchi M, Karouby D, Coliat P, Pivot X, Petit T, Cox DG, Goepp L, Bender L, Trensz P. A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer. Breast Cancer Res Treat 2023; 198:23-29. [PMID: 36562910 DOI: 10.1007/s10549-022-06844-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2022] [Accepted: 12/09/2022] [Indexed: 12/24/2022]
Abstract
PURPOSE A 4-weekly schedule of pegylated liposomal doxorubicin (PLD) has been approved for the treatment of metastatic breast cancer (MBC). Phase II trials have suggested interest in a 2-weekly regimen. This study aimed to compare the efficacy and safety of these two schedules. METHODS Data from MBC patients treated with PLD between 2011 and 2021 were retrospectively collected. The objective was to demonstrate the noninferiority of the 2-weekly versus the 4-weekly schedule in terms of 6-month progression-free survival (PFS). The prespecified noninferiority margin was calculated as 1.20. A propensity score to receive either schedule was estimated using a gradient boosting algorithm. Survival analyses using Cox regression models weighted by the propensity score were performed to compare the schedules. RESULTS Among the 192 patients included, 96 (50%) underwent each schedule. The median number of previous systemic therapies was 4 (IQR, 3 to 6). Anthracyclines were previously given in early breast cancer in 63.9% of patients. The median follow-up was 10.0 months (IQR, 5.0 to 20.1). A comparable distribution of adverse events was observed. The median PFS was 3.2 months (95% CI, 2.9 to 3.9), and the median overall survival was 12.1 months (95% CI, 10.8 to 14.9). The weighted hazard ratio for PFS was 1.12 (90% CI, 0.82 to 1.54), including the noninferiority boundaries. CONCLUSION PLD appeared to be a well-tolerated drug in this heavily pretreated MBC population. The efficacy and safety of the 2-weekly schedule did not provide any advantage, suggesting no interest in changing the registered regimen.
Collapse
Affiliation(s)
- H Bischoff
- Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France.
| | - C Bigot
- Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| | - F Moinard-Butot
- Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| | - C Pflumio
- Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| | - C Fischbach
- Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| | - M Kalish
- Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| | - J E Kurtz
- Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| | - L Pierard
- Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| | - M Demarchi
- Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| | - D Karouby
- Pharmacy, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| | - P Coliat
- Pharmacy, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| | - X Pivot
- Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| | - T Petit
- Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| | - D G Cox
- Statistics, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| | - L Goepp
- Statistics, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| | - L Bender
- Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| | - P Trensz
- Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67033, Strasbourg, France
| |
Collapse
|
6
|
Mallard J, Hucteau E, Schott R, Trensz P, Pflumio C, Kalish-Weindling M, Favret F, Pivot X, Hureau TJ, Pagano AF. Early skeletal muscle deconditioning and reduced exercise capacity during (neo)adjuvant chemotherapy in patients with breast cancer. Cancer 2023; 129:215-225. [PMID: 36397290 PMCID: PMC10099272 DOI: 10.1002/cncr.34533] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Revised: 09/17/2022] [Accepted: 10/06/2022] [Indexed: 11/21/2022]
Abstract
BACKGROUND Fatigue is a hallmark of breast cancer and is associated with skeletal muscle deconditioning. If cancer-related fatigue occurs early during chemotherapy (CT), the development of skeletal muscle deconditioning and its effect on exercise capacity remain unclear. The aim of this study was to investigate the evolution of skeletal muscle deconditioning and exercise capacity in patients with early-stage breast cancer during CT. METHODS Patients with breast cancer had a visit before undergoing CT, at 8 weeks, and at the end of chemotherapy (post-CT). Body composition was determined through bioelectrical impedance analysis. Knee extensor, handgrip muscle force and fatigue was quantified by performing maximal voluntary isometric contractions and exercise capacity using the 6-min walking test. Questionnaires were also administered to evaluate quality of life, cancer-related fatigue, and physical activity level. RESULTS Among the 100 patients, reductions were found in muscle mass (-2.3%, p = .002), exercise capacity (-6.7%, p < .001), and knee extensor force (-4.9%, p < .001) post-CT, which occurred within the first 8 weeks of treatment with no further decrease thereafter. If muscle fatigue did not change, handgrip muscle force decreased post-CT only (-2.5%, p = .001), and exercise capacity continued to decrease between 8 weeks and post-CT (-4.6%, p < .001). Quality of life and cancer-related fatigue were impaired after 8 weeks (p < .001) and remained stable thereafter, whereas the physical activity level remained stable during chemotherapy. CONCLUSIONS Similar to cancer-related fatigue, skeletal muscle deconditioning and reduced exercise capacity occurred early during breast cancer CT. Thus, it appears essential to prevent these alterations through exercise training implemented during CT.
Collapse
Affiliation(s)
- Joris Mallard
- Biomedicine Research Centre of Strasbourg (CRBS), Mitochondria, oxidative stress, and muscular protection laboratory (UR 3072), Strasbourg, France.,Faculty of Sport Sciences, European Centre for Education, Research and Innovation in Exercise Physiology (CEERIPE), University of Strasbourg, Strasbourg, France.,Institute of Cancerology Strasbourg Europe (ICANS), Strasbourg, France
| | - Elyse Hucteau
- Biomedicine Research Centre of Strasbourg (CRBS), Mitochondria, oxidative stress, and muscular protection laboratory (UR 3072), Strasbourg, France.,Faculty of Sport Sciences, European Centre for Education, Research and Innovation in Exercise Physiology (CEERIPE), University of Strasbourg, Strasbourg, France.,Institute of Cancerology Strasbourg Europe (ICANS), Strasbourg, France
| | - Roland Schott
- Institute of Cancerology Strasbourg Europe (ICANS), Strasbourg, France
| | - Philippe Trensz
- Institute of Cancerology Strasbourg Europe (ICANS), Strasbourg, France
| | - Carole Pflumio
- Institute of Cancerology Strasbourg Europe (ICANS), Strasbourg, France
| | | | - Fabrice Favret
- Biomedicine Research Centre of Strasbourg (CRBS), Mitochondria, oxidative stress, and muscular protection laboratory (UR 3072), Strasbourg, France.,Faculty of Sport Sciences, European Centre for Education, Research and Innovation in Exercise Physiology (CEERIPE), University of Strasbourg, Strasbourg, France
| | - Xavier Pivot
- Institute of Cancerology Strasbourg Europe (ICANS), Strasbourg, France
| | - Thomas J Hureau
- Biomedicine Research Centre of Strasbourg (CRBS), Mitochondria, oxidative stress, and muscular protection laboratory (UR 3072), Strasbourg, France.,Faculty of Sport Sciences, European Centre for Education, Research and Innovation in Exercise Physiology (CEERIPE), University of Strasbourg, Strasbourg, France
| | - Allan F Pagano
- Biomedicine Research Centre of Strasbourg (CRBS), Mitochondria, oxidative stress, and muscular protection laboratory (UR 3072), Strasbourg, France.,Faculty of Sport Sciences, European Centre for Education, Research and Innovation in Exercise Physiology (CEERIPE), University of Strasbourg, Strasbourg, France
| |
Collapse
|
7
|
Martin S, Pflumio C, Trensz P, Schaff-Wendling F, Weindling MK, Fischbach C, Pierard L, Limacher JM, Nader R, Velten M, Petit T. Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak. Clin Breast Cancer 2023; 23:32-37. [PMID: 36414498 PMCID: PMC9558751 DOI: 10.1016/j.clbc.2022.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Revised: 09/27/2022] [Accepted: 10/09/2022] [Indexed: 01/08/2023]
Abstract
BACKGROUND The impact of some hasty medical decision made during the first wave of the Coronavirus Disease 2019 (COVID-19) remains unknown. We have evaluated the consequences of one of these precautionary measures: the withdrawal of the cyclin D-dependent kinases 4/6 inhibitor (CDK4/6i) in patients whose metastatic disease was controlled by a combination of endocrine treatment and CDK 4/6i. METHOD This study was noninterventional, retrospective, multicentric, and included 60 patients with HR+ HER2- metastatic disease. Their disease was controlled with the combination of endocrine treatment and CDK 4/6i. The CDK 4/6i was stopped for two months during the first COVID-19 outbreak. A univariate analysis was performed to assess the risk factors associated with disease progression. RESULTS During this therapeutic break, 22 (37 %) patients had a radiological and/or clinical disease progression. Among them, the CDK 4/6i was re-introduced to 16 patients (n = 16/22; 73 %). A new line of treatment (chemotherapy or targeted therapy) was initiated due to the rapid symptomatic tumor progression in four patients (n = 4/22; 18 %). Two patients (n = 2/22) died in visceral crisis before another anti-tumoral treatment was introduced. In univariate analysis, the presence of liver metastases increased the risk of metastatic disease progression during the withdrawal of the CDK 4/6 (OR = 6.6; 95 % CI 1.87-23.22; P= .0033). CONCLUSION Progression was observed in 37% of patients during the two-month treatment interruption of the CDK 4/6i. A prolonged CDK 4/6i treatment interruption in patients with clinical benefit on endocrine treatment does not seem to be a reasonable option in light of these results.
Collapse
Affiliation(s)
- Sophie Martin
- Department of Medical Oncology, Strasbourg Cancer Institute (ICANS), Strasbourg, France.
| | - Carole Pflumio
- Department of Medical Oncology, Strasbourg Cancer Institute (ICANS), Strasbourg, France
| | - Philippe Trensz
- Department of Medical Oncology, Strasbourg Cancer Institute (ICANS), Strasbourg, France
| | | | | | - Cathie Fischbach
- Department of Medical Oncology, Strasbourg Cancer Institute (ICANS), Strasbourg, France
| | - Laure Pierard
- Department of Medical Oncology, Strasbourg Cancer Institute (ICANS), Strasbourg, France
| | - Jean-Marc Limacher
- Department of Medical Oncology and Clinical Hematology, Hôpital Louis Pasteur, Colmar, France
| | - Rita Nader
- Department of Medical Oncology, Strasbourg Cancer Institute (ICANS), Strasbourg, France
| | - Michel Velten
- Department of Epidemiology and Public Health, Strasbourg University, Inserm, Strasbourg, France,Department of Public Health, ICANS, Strasbourg, France
| | - Thierry Petit
- Department of Medical Oncology, Strasbourg Cancer Institute (ICANS), Strasbourg, France
| |
Collapse
|
8
|
Mallard J, Hucteau E, Bender L, Charlot A, Debrut L, Pflumio C, Trensz P, Schott R, Favret F, Pivot X, Hureau TJ, Pagano AF. Development of skeletal muscle atrophy and intermuscular adipose tissue in early breast cancer patients treated with chemotherapy. Am J Physiol Cell Physiol 2022; 323:C1325-C1332. [PMID: 36094434 PMCID: PMC9576176 DOI: 10.1152/ajpcell.00373.2022] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
Chemotherapy is a common therapy to treat patients with breast cancer but also leads to skeletal muscle deconditioning. Skeletal muscle deconditioning is multifactorial and intermuscular adipose tissue (IMAT) accumulation is closely linked to muscle dysfunction. To date, there is no clinical study available investigating IMAT development through a longitudinal protocol and the underlying mechanisms remain unknown. Our study was dedicated to investigating IMAT content in patients with early breast cancer who were treated with chemotherapy and exploring the subsequent cellular mechanisms involved in its development. We included 13 women undergoing chemotherapy. Muscle biopsies and ultrasonography assessment were performed before and after chemotherapy completion. Histological and Western blotting analyses were conducted. We found a substantial increase in protein levels of three mature adipocyte markers (perilipin, +901%; adiponectin, +135%; FABP4, +321%; P < 0.05). These results were supported by an increase in oil red O-positive staining (+358%; P < 0.05). A substantial increase in PDGFRα protein levels was observed (+476%; P < 0.05) highlighting an increase in fibro-adipogenic progenitors (FAPs) content. The cross-sectional area of the vastus lateralis muscle fibers substantially decreased (−21%; P < 0.01), and muscle architecture was altered, as shown by a decrease in fascicle length (−15%; P < 0.05) and a decreasing trend in muscle thickness (−8%; P = 0.08). We demonstrated both IMAT development and muscle atrophy in patients with breast cancer who were treated with chemotherapy. FAPs, critical stem cells inducing both IMAT development and skeletal muscle atrophy, also increased, suggesting that FAPs likely play a critical role in the skeletal muscle deconditioning observed in patients with breast cancer who were treated with chemotherapy.
Collapse
Affiliation(s)
- Joris Mallard
- Faculté de médecine, maïeutique et sciences de la santé, UR 3072, "Mitochondrie, Stress oxydant, Protection musculaire", Université de Strasbourg, France.,Faculté des Sciences du Sport, Centre Européen d'Enseignement de Recherche et d'Innovation en Physiologie de l'Exercice (CEERIPE), Université de Strasbourg, France.,Institut de Cancérologie Strasbourg Europe (ICANS), France
| | - Elyse Hucteau
- Faculté de médecine, maïeutique et sciences de la santé, UR 3072, "Mitochondrie, Stress oxydant, Protection musculaire", Université de Strasbourg, France.,Faculté des Sciences du Sport, Centre Européen d'Enseignement de Recherche et d'Innovation en Physiologie de l'Exercice (CEERIPE), Université de Strasbourg, France.,Institut de Cancérologie Strasbourg Europe (ICANS), France
| | - Laura Bender
- Institut de Cancérologie Strasbourg Europe (ICANS), France
| | - Anouk Charlot
- Faculté de médecine, maïeutique et sciences de la santé, UR 3072, "Mitochondrie, Stress oxydant, Protection musculaire", Université de Strasbourg, France
| | - Léa Debrut
- Faculté de médecine, maïeutique et sciences de la santé, UR 3072, "Mitochondrie, Stress oxydant, Protection musculaire", Université de Strasbourg, France
| | - Carole Pflumio
- Institut de Cancérologie Strasbourg Europe (ICANS), France
| | | | - Roland Schott
- Institut de Cancérologie Strasbourg Europe (ICANS), France
| | - Fabrice Favret
- Faculté de médecine, maïeutique et sciences de la santé, UR 3072, "Mitochondrie, Stress oxydant, Protection musculaire", Université de Strasbourg, France.,Faculté des Sciences du Sport, Centre Européen d'Enseignement de Recherche et d'Innovation en Physiologie de l'Exercice (CEERIPE), Université de Strasbourg, France
| | - Xavier Pivot
- Institut de Cancérologie Strasbourg Europe (ICANS), France
| | - Thomas J Hureau
- Faculté de médecine, maïeutique et sciences de la santé, UR 3072, "Mitochondrie, Stress oxydant, Protection musculaire", Université de Strasbourg, France.,Faculté des Sciences du Sport, Centre Européen d'Enseignement de Recherche et d'Innovation en Physiologie de l'Exercice (CEERIPE), Université de Strasbourg, France
| | - Allan F Pagano
- Faculté de médecine, maïeutique et sciences de la santé, UR 3072, "Mitochondrie, Stress oxydant, Protection musculaire", Université de Strasbourg, France.,Faculté des Sciences du Sport, Centre Européen d'Enseignement de Recherche et d'Innovation en Physiologie de l'Exercice (CEERIPE), Université de Strasbourg, France
| |
Collapse
|
9
|
Mallard J, Hucteau E, Charles AL, Bender L, Baeza C, Pélissie M, Trensz P, Pflumio C, Kalish-Weindling M, Gény B, Schott R, Favret F, Pivot X, Hureau TJ, Pagano AF. Chemotherapy impairs skeletal muscle mitochondrial homeostasis in early breast cancer patients. J Cachexia Sarcopenia Muscle 2022; 13:1896-1907. [PMID: 35373507 PMCID: PMC9178151 DOI: 10.1002/jcsm.12991] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Revised: 02/22/2022] [Accepted: 03/07/2022] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Chemotherapy is extensively used to treat breast cancer and is associated with skeletal muscle deconditioning, which is known to reduce patients' quality of life, treatment efficiency, and overall survival. To date, skeletal muscle mitochondrial alterations represent a major aspect explored in breast cancer patients; nevertheless, the cellular mechanisms remain relatively unknown. This study was dedicated to investigating overall skeletal muscle mitochondrial homeostasis in early breast cancer patients undergoing chemotherapy, including mitochondrial quantity, function, and dynamics. METHODS Women undergoing (neo)adjuvant anthracycline-cyclophosphamide and taxane-based chemotherapy participated in this study (56 ± 12 years). Two muscle biopsies were collected from the vastus lateralis muscle before the first and after the last chemotherapy administration. Mitochondrial respiratory capacity, reactive oxygen species production, and western blotting analyses were performed. RESULTS Among the 11 patients, we found a decrease in key markers of mitochondrial quantity, reaching -52.0% for citrate synthase protein levels (P = 0.02) and -38.2% for VDAC protein levels (P = 0.04). This mitochondrial content loss is likely explained by reduced mitochondrial biogenesis, as evidenced by a decrease in PGC-1α1 protein levels (-29.5%; P = 0.04). Mitochondrial dynamics were altered, as documented by a decrease in MFN2 protein expression (-33.4%; P = 0.01), a key marker of mitochondrial outer membrane fusion. Mitochondrial fission is a prerequisite for mitophagy activation, and no variation was found in either key markers of mitochondrial fission (Fis1 and DRP1) or mitophagy (Parkin, PINK1, and Mul1). Two contradictory hypotheses arise from these results: defective mitophagy, which probably increases the number of damaged and fragmented mitochondria, or a relative increase in mitophagy through elevated mitophagic potential (Parkin/VDAC ratio; +176.4%; P < 0.02). Despite no change in mitochondrial respiratory capacity and COX IV protein levels, we found an elevation in H2 O2 production (P < 0.05 for all substrate additions) without change in antioxidant enzymes. We investigated the apoptosis pathway and found an increase in the protein expression of the apoptosis initiation marker Bax (+72.0%; P = 0.04), without variation in the anti-apoptotic protein Bcl-2. CONCLUSIONS This study demonstrated major mitochondrial alterations subsequent to chemotherapy in early breast cancer patients: (i) a striking reduction in mitochondrial biogenesis, (ii) altered mitochondrial dynamics and potential mitophagy defects, (iii) exacerbated H2 O2 production, and (iv) increased initiation of apoptosis. All of these alterations likely explain, at least in part, the high prevalence of skeletal muscle and cardiorespiratory deconditioning classically observed in breast cancer patients.
Collapse
Affiliation(s)
- Joris Mallard
- Faculté de médecine, maïeutique et sciences de la santé, "Mitochondrie, Stress oxydant, Protection musculaire", Université de Strasbourg, Strasbourg, France.,Faculté des Sciences du Sport, Centre Européen d'Enseignement de Recherche et d'Innovation en Physiologie de l'Exercice (CEERIPE), Université de Strasbourg, Strasbourg, France.,Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Elyse Hucteau
- Faculté de médecine, maïeutique et sciences de la santé, "Mitochondrie, Stress oxydant, Protection musculaire", Université de Strasbourg, Strasbourg, France.,Faculté des Sciences du Sport, Centre Européen d'Enseignement de Recherche et d'Innovation en Physiologie de l'Exercice (CEERIPE), Université de Strasbourg, Strasbourg, France.,Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Anne-Laure Charles
- Faculté de médecine, maïeutique et sciences de la santé, "Mitochondrie, Stress oxydant, Protection musculaire", Université de Strasbourg, Strasbourg, France
| | - Laura Bender
- Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Claire Baeza
- Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Mathilde Pélissie
- Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Philippe Trensz
- Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Carole Pflumio
- Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | | | - Bernard Gény
- Faculté de médecine, maïeutique et sciences de la santé, "Mitochondrie, Stress oxydant, Protection musculaire", Université de Strasbourg, Strasbourg, France.,Faculté des Sciences du Sport, Centre Européen d'Enseignement de Recherche et d'Innovation en Physiologie de l'Exercice (CEERIPE), Université de Strasbourg, Strasbourg, France
| | - Roland Schott
- Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Fabrice Favret
- Faculté de médecine, maïeutique et sciences de la santé, "Mitochondrie, Stress oxydant, Protection musculaire", Université de Strasbourg, Strasbourg, France.,Faculté des Sciences du Sport, Centre Européen d'Enseignement de Recherche et d'Innovation en Physiologie de l'Exercice (CEERIPE), Université de Strasbourg, Strasbourg, France
| | - Xavier Pivot
- Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Thomas J Hureau
- Faculté de médecine, maïeutique et sciences de la santé, "Mitochondrie, Stress oxydant, Protection musculaire", Université de Strasbourg, Strasbourg, France.,Faculté des Sciences du Sport, Centre Européen d'Enseignement de Recherche et d'Innovation en Physiologie de l'Exercice (CEERIPE), Université de Strasbourg, Strasbourg, France
| | - Allan F Pagano
- Faculté de médecine, maïeutique et sciences de la santé, "Mitochondrie, Stress oxydant, Protection musculaire", Université de Strasbourg, Strasbourg, France.,Faculté des Sciences du Sport, Centre Européen d'Enseignement de Recherche et d'Innovation en Physiologie de l'Exercice (CEERIPE), Université de Strasbourg, Strasbourg, France
| |
Collapse
|
10
|
Gaillard V, Lhuillier A, Bigot C, Pierard L, Trensz P, Burgy M, Schuster C, Malouf G, Fritsch A, Lang H, Tricard T, Borchiellini D, Geoffrois L, Barthelemy P. Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study. Support Care Cancer 2022; 30:6583-6591. [PMID: 35484315 DOI: 10.1007/s00520-022-07088-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2021] [Accepted: 04/21/2022] [Indexed: 10/18/2022]
Abstract
BACKGROUND Tyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose downregulation, and optimal management of AEs is needed to maintain an efficient dose intensity (DI). The aim of our study was to evaluate the impact of an app-based and nurse-led supportive-care program on DI in mRCC patients. METHOD This multicenter (n = 3), retrospective study evaluated all consecutive mRCC patients who participated in the AKO@dom program, which consisted of an app-based and nurse-led weekly patient evaluation at home during the first 3 months of TKI intake. Treatment patterns and modifications were described, and the mean DI (mDI) was calculated at the end of AKO@dom. RESULTS Eighty-nine patients were included: 12 had sunitinib, 18 pazopanib, 12 axitinib, and 47 cabozantinib. Median age was 69 years (60-76). TKIs were mainly initiated at standard doses except for cabozantinib (53% started at 40 mg/day); 71% had prior systemic treatment. Nine patients discontinued permanent treatment during the program. Thirty-two patients required ≥ 1 dose interruption, and 29% experienced ≥ 1 grade 3 AE of any type. The mDI (in mg/day) at 3 months was 34.4 ± 17.7 for sunitinib, 672.8 ± 144 for pazopanib, 8.6 ± 2.6 for axitinib, and 40 (36-48) for cabozantinib. Fifty-five patients [68.75% (95% CI: 57-78%)] had a mDI ≥ than reported in the literature. Overall survival at 12 months was 64.2% (CI 95%: 55-75%). CONCLUSION The AKO@dom program allowed 68.75% of patients to maintain a high dose intensity after 3 months of TKI treatment. The impact on survival outcomes needs to be evaluated in randomized clinical trials.
Collapse
Affiliation(s)
- Victor Gaillard
- Department of Urology, University Hospital, Strasbourg, France.
| | - Albane Lhuillier
- Department of Medical Oncology, Institut de Cancérologie de Lorraine (ICL), Nancy, France
| | - Cécile Bigot
- Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Laure Pierard
- Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Philippe Trensz
- Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Mickael Burgy
- Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Caroline Schuster
- Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Gabriel Malouf
- Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Aurélie Fritsch
- Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France
| | - Hervé Lang
- Department of Urology, University Hospital, Strasbourg, France
| | | | | | - Lionnel Geoffrois
- Department of Medical Oncology, Institut de Cancérologie de Lorraine (ICL), Nancy, France
| | | |
Collapse
|
11
|
Martin S, Pflumio C, Trensz P, Schaff-Wendling F, Kalish M, Fischbach C, Pierard L, Limacher JM, Velten M, Petit T. Abstract P1-17-07: Consequences of stopping a 4/6 cyclin D-dependent kinase Inhibitor in metastatic breast cancer patients with clinical benefit on endocrine treatment, in the context of the COVID-19 outbreak. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p1-17-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The impact of some medical decisions hurriedly taken during the COVID-19 first wave remains unknown. We tried to assess the consequences of one of these precautionary measures, namely the interruption of a 4/6 cyclin D-dependent kinase inhibitor (CDK4/6i) in metastatic patients with clinical benefit (complete response/partial response and patients with stable disease for at least 6 months) on endocrine treatment (ET). The main reason for this interruption was to limit the risk of myelosuppression (assumed as a serious risk factor for COVID-19) and other adverse effects that could overlap with symptoms and clinical signs described in the SARS-CoV-2 infection. Methods: We included 60 patients (median age: 64 years old) in whom the CDK4/6i was stopped during the first COVID-19 outbreak. It was a non-interventional, retrospective, multicentric study. A univariate analysis was performed to assess risk factors associated with disease progression: odds ratios (OR) were estimated along with their confidence intervals (CI). Key patient characteristics, all included in the statistical model, are presented in Table 1. Results: The average duration of a CDK4/6i interruption was 8 weeks. During this therapeutic break, 22 (37 %) patients had a radiological and/or clinical progression of the disease. Among them, CDK4/6i were taken back for the majority of patients (n=16/22; 73 %) when the sanitary situation improved.For four patients (n=4/22; 18 %), a new specific treatment (chemotherapy or targeted therapy) was initiated for rapid or symptomatic tumor progression. Two patients died while CDK4/6i was withdrawn.All the results of the univariate analysis are summarized in Table 2. During the CDK4/6i discontinuation, the risk of disease progression was significantly increased in the presence of liver metastases. This was the only variable with a significant effect in univariate analysis.. Although not statistically significant, the risk of disease progression was higher when CDK4/6i withdrawal was longer, when patients had a more aggressive breast cancer (Luminal B) and when the tumor was considered as resistant to ET. Conclusions: The importance of maintaining the cell cycle inhibitor in addition to ET does not seem to be debatable as 36 % of patients progressed during CDK4/6i withdrawal. This is important in clinical practice when the question of CDK4/6i discontinuation arises for other reasons (analgesic radiotherapy or programmed surgery for example). Special attention should be paid to patients with liver metastases for whom stopping such a treatment seems to accelerate the natural course of the disease.
Table 1.Population characteristics and evaluated variables.(CDK4/6i: 4/6 cyclin D-dependent kinase inhibitor)N. (%)Patients and variablesPatients(n=60)Disease progression (n=22)Disease stability(n=38)Age, years (upon discontinuation of CDK/6i)[35-50]12 (20)4 (18)8 (21)[50-65]19 (32)6 (27)13 (34)[65-93]29 (48)12 (55)17 (45)Cancer typeLuminal A26 (43)11 (50)15 (40)Luminal B34 (57)11 (50)23 (61)Endocrine treatmentPrimary resistance6 (10)3 (14)3 (8)Secondary resistance34 (57)15 (68)19 (50)Sensibility20 (33)4 (18)16 (42)Time between initial and metastasis diagnosisMetastases at diagnosis18 (30)5 (23)13 (34)< 5 years16 (27)8 (36)8 (21)> 5 years26 (43)9 (41)17 (45)Metastatic sitesExclusives bones metastases14 (23)4 (18)10 (26)Liver metastases (not exclusive)16 (27)11 (50)5 (13)Visceral metastases (not hepatic)30 (50)7 (32)23 (61)Duration of CDK4/6i treatment before discontinuation< 6 months25 (42)8 (36)17 (45)Between 6 months and 12 months17 (28)6 (27)11 (29)> 12 months18 (30)8 (36)10 (26)Duration of CDK4/6i treatment discontinuation< 2 months27 (45)7 (32)20 (53)≥ 2 months33 (55)15 (68)18 (47)
Table 2.Univariate analysis and odds ratio for disease progression.(OR: odds ratio, CI: confidence interval, vs: versus, CDK4/6i: 4/6 cyclin D-dependent kinase inhibitor)OR95 % CIP valueAge, years (at discontinuation of CDK/6i)[35-50]1.76[50-65].92[0.20-4.31][65-93]1.41[0.35-5.78]Cancer typeLuminal A1.15Luminal B2.49[0.71-8.70]Endocrine treatmentSensibility1.07Primary or secondary resistance3.27[0.93-11.54]Disease stage at diagnosisMetastasis at initial diagnosis1.35No metastasis at initial diagnosis0.56[0.17-1.88]Metastatic sitesExclusives bones metastases1.01Liver metastases (not exclusive)5.50[1.14-26.41]Visceral metastases (not hepatic)0.76[0.18-3.20]Duration of CDK4/6i treatment before discontinuation< 6 months1.70Between 6 months and 12 months1.16[0.31-4.26]> 12 months1.70[0.49-5.95]Duration of CDK4/6i treatment discontinuation< 2 months1.12≥ 2 months2.38[0.79-7.15]
Citation Format: Sophie Martin, Carole Pflumio, Philippe Trensz, Frederique Schaff-Wendling, Michal Kalish, Cathie Fischbach, Laure Pierard, Jean-Marc Limacher, Michel Velten, Thierry Petit. Consequences of stopping a 4/6 cyclin D-dependent kinase Inhibitor in metastatic breast cancer patients with clinical benefit on endocrine treatment, in the context of the COVID-19 outbreak [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-17-07.
Collapse
Affiliation(s)
- Sophie Martin
- Institut de Cancérologie Strasbourg - Europe, Strasbourg, France
| | - Carole Pflumio
- Institut de Cancérologie Strasbourg - Europe, Strasbourg, France
| | - Philippe Trensz
- Institut de Cancérologie Strasbourg - Europe, Strasbourg, France
| | | | - Michal Kalish
- Institut de Cancérologie Strasbourg - Europe, Strasbourg, France
| | - Cathie Fischbach
- Institut de Cancérologie Strasbourg - Europe, Strasbourg, France
| | - Laure Pierard
- Institut de Cancérologie Strasbourg - Europe, Strasbourg, France
| | | | - Michel Velten
- Institut de Cancérologie Strasbourg - Europe, Strasbourg, France
| | - Thierry Petit
- Institut de Cancérologie Strasbourg - Europe, Strasbourg, France
| |
Collapse
|
12
|
Despinasse M, Schohn A, Bimboes A, Trensz P, Sirlin F, Chiappa P, Frasie V. COVID-19 et modification des aides à domicile : étude prospective auprès de 100 patients suivis en CLCC. Bull Cancer 2022; 109:396-408. [PMID: 35219501 PMCID: PMC8841147 DOI: 10.1016/j.bulcan.2022.01.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2021] [Revised: 01/15/2022] [Accepted: 01/17/2022] [Indexed: 11/29/2022]
Abstract
Contexte Lors de l’épidémie de la COVID-19, les mesures de confinement ont été associées à des recommandations professionnelles pour la prise en charge des patients. Nous avons constaté auprès des patients suivis en service de soins de support que certains actes à domicile n’étaient plus effectués. L’objectif de notre étude est de déterminer l’impact du confinement sur les aides à domicile des patients atteints de cancer. Matériels et méthodes Cette étude observationnelle descriptive monocentrique et prospective a été réalisée en Hôpital de jour de soins de support du 20 avril au 15 mai 2020 auprès de 100 patients. Ils étaient interrogés sur les aides à domicile et leurs fréquences avant et après le confinement. Notre étude a reçu l’avis favorable du Comité d’éthique des hôpitaux universitaires de Strasbourg. Résultats Environ deux tiers des patients ont subi une modification de leurs aides à domicile. Un arrêt du passage d’un professionnel à domicile a concerné 40 % d’entre eux et une diminution de la fréquence, 10 % d’entre eux. Certaines populations ont été significativement plus touchées : les patients de statut OMS 3 et 4, les femmes, les patients vivant seuls et ceux atteints d’un handicap moteur. Un arrêt de la réalisation d’un acte habituellement réalisé par un professionnel à domicile a concerné 49 % des patients avec un report de ces tâches sur les patients ou leurs aidants. Conclusion Notre étude montre un impact fort du confinement sur les aides à domicile en dépit des recommandations émises sur la continuité des soins. Notre étude souligne l’importance de veiller à l’accès aux soins des plus vulnérables.
Collapse
|
13
|
Gaillard V, Lhuillier A, Bigot C, Pierard L, Trensz P, Schuster C, Malouf G, Fritsch A, Borchiellini D, Geoffrois L, Barthelemy P. CN54 Impact of the app-based and nurse-led supportive care program AKO@dom on dose-intensity of oral targeted therapies in patients with metastatic renal cell cancer: A multicentric observational retrospective study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
14
|
Trensz P, Calvel L, Kurtz J. The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer? Ann Oncol 2018; 29:1601. [DOI: 10.1093/annonc/mdy186] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|